DE60128368D1 - Diagnose und behandlung von prostatakrebs - Google Patents

Diagnose und behandlung von prostatakrebs

Info

Publication number
DE60128368D1
DE60128368D1 DE60128368T DE60128368T DE60128368D1 DE 60128368 D1 DE60128368 D1 DE 60128368D1 DE 60128368 T DE60128368 T DE 60128368T DE 60128368 T DE60128368 T DE 60128368T DE 60128368 D1 DE60128368 D1 DE 60128368D1
Authority
DE
Germany
Prior art keywords
hne
gated
voltage
nucleic acid
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60128368T
Other languages
English (en)
Other versions
DE60128368T2 (de
Inventor
Mustafa Bilgin Djamgoz
Scott Paton Fraser
James Kenneth Diss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Innovations Ltd filed Critical Imperial Innovations Ltd
Application granted granted Critical
Publication of DE60128368D1 publication Critical patent/DE60128368D1/de
Publication of DE60128368T2 publication Critical patent/DE60128368T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60128368T 2000-09-02 2001-09-03 Diagnose und behandlung von prostatakrebs Expired - Lifetime DE60128368T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0021617 2000-09-02
GBGB0021617.6A GB0021617D0 (en) 2000-09-02 2000-09-02 Diagnosis and treatment of cancer
PCT/GB2001/003940 WO2002018637A2 (en) 2000-09-02 2001-09-03 Diagnosis and treatment of prostate cancer

Publications (2)

Publication Number Publication Date
DE60128368D1 true DE60128368D1 (de) 2007-06-21
DE60128368T2 DE60128368T2 (de) 2008-01-10

Family

ID=9898761

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60128368T Expired - Lifetime DE60128368T2 (de) 2000-09-02 2001-09-03 Diagnose und behandlung von prostatakrebs

Country Status (10)

Country Link
US (2) US20060166194A1 (de)
EP (1) EP1313882B1 (de)
JP (1) JP2004507254A (de)
AT (1) ATE361993T1 (de)
AU (1) AU2001282364A1 (de)
CY (1) CY1107715T1 (de)
DE (1) DE60128368T2 (de)
ES (1) ES2288979T3 (de)
GB (1) GB0021617D0 (de)
WO (1) WO2002018637A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2443968A1 (en) * 2001-04-12 2002-10-24 Imperial College Innovations Limited Diagnosis and treatment of cancer: i
AU2002251286A1 (en) * 2001-04-12 2002-10-28 Imperial College Innovations Limited Diagnosis and treatment of cancer:ii
CA2553745A1 (en) * 2004-01-21 2005-08-04 University Of Utah Research Foundation Mutant sodium channel nav1.7 and methods related thereto
AU2005249492B2 (en) * 2004-05-27 2011-09-22 The Regents Of The University Of Colorado Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
US20080070792A1 (en) 2006-06-14 2008-03-20 Roland Stoughton Use of highly parallel snp genotyping for fetal diagnosis
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
EP2220123A1 (de) * 2007-11-19 2010-08-25 Genentech, Inc. Zusammensetzungen und verfahren zur inhibierung der tumorprogression
GB0811360D0 (en) * 2008-06-20 2008-07-30 Imp Innovations Ltd Methods
ES2620012T3 (es) 2008-09-20 2017-06-27 The Board Of Trustees Of The Leland Stanford Junior University Diagnóstico no invasivo de la aneuploidia fetal por secuenciación
CA2773983A1 (en) 2009-09-11 2011-03-17 University Of Utah Research Foundation Mutant sodium channel nav1.7 and methods related thereto
AU2012228990B2 (en) 2011-03-16 2017-04-06 Amgen Inc. Potent and selective inhibitors of Nav1.3 and Nav1.7
AR096927A1 (es) 2013-03-12 2016-02-10 Amgen Inc INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
UY35397A (es) 2013-03-12 2014-10-31 Amgen Inc INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
EP3810776A1 (de) * 2018-06-22 2021-04-28 F. Hoffmann-La Roche AG Oligonukleotide zur modulation der scn9a-expression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE407207T1 (de) * 1994-11-02 2008-09-15 Trophix Pharm Inc Natrium-ionenkanäle spezifisch für das periphäre nervensystem, dna welche diese kodiert, wirkstoff-suche und methoden zu deren herstellung und verwendung
US7312043B2 (en) * 2000-07-10 2007-12-25 Vertex Pharmaceuticals (San Diego) Llc Ion channel assay methods

Also Published As

Publication number Publication date
WO2002018637A2 (en) 2002-03-07
GB0021617D0 (en) 2000-10-18
EP1313882A2 (de) 2003-05-28
US20060166194A1 (en) 2006-07-27
WO2002018637A3 (en) 2002-11-21
JP2004507254A (ja) 2004-03-11
US20080145859A1 (en) 2008-06-19
US7759078B2 (en) 2010-07-20
CY1107715T1 (el) 2013-04-18
ATE361993T1 (de) 2007-06-15
EP1313882B1 (de) 2007-05-09
DE60128368T2 (de) 2008-01-10
ES2288979T3 (es) 2008-02-01
AU2001282364A1 (en) 2002-03-13

Similar Documents

Publication Publication Date Title
CY1107715T1 (el) Διαγνωση και αγωγη του καρκινου του προστατη
WO2002083945A3 (en) Diagnosis and treatment of cancer: i
ATE353974T1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
Nekoofar et al. pH of pus collected from periapical abscesses
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
DE69933989D1 (de) Biomarker und targets für die diagnose, prognose und behandlung von prostat krankheiten
EA200501772A1 (ru) Способы измерения экспрессии генов из фиксированного и залитого в парафин образца ткани
BR0110091A (pt) Composições e processos para terapia e diagnóstico de câncer de mama
MXPA04000080A (es) Metodos de diagnostico de cancer en la vejiga, composiciones y metodos de rastreo de moduladores de cancer en la vejiga.
ATE266723T1 (de) Lösung die chaotropische mittel enthält und verwendung dieser lösung in verfahren zur isolierung von dna, rna und proteinen
WO2004110345A3 (en) Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
WO2002046222A3 (en) Compositions and methods for diagnosing alzheimer's disease
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
ATE364096T1 (de) Verfahren zur diagnose und therapie von schizophrenie
ATE413881T1 (de) Verfahren und zubereitungen um resistenz gegen biologische oder chemische therapien zu überwinden
TR200003159T2 (tr) Antipicornaviral bileşikler, hazırlanışları ve kullanımları
WO2000009754A3 (en) HUMAN STEAROYL-CoA DESATURASE-RELATED COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
ATE375389T1 (de) Verfahren zur diagnose, prognose und behandlung von glaukom und verwandten erkrankungen
BRPI0407213A (pt) Método de emprego da elevação de marinobufagenina na determinação da presença de pré-eclampsia e aparelhos relacionados
DE69920681D1 (de) Humaner k+ ionenkanal und therapeutische verwendungen davon
BR0312483A (pt) Anticorpos e seus usos
Schoser et al. A large german kindred with cold‐aggravated myotonia and a heterozygous A1481D mutation in the SCN4A gene
FR2756845B1 (fr) Sequence nucleotidique codant pour une flavine monooxygenase , proteine correspondante et composition destinee au diagnostic et a la therapie du glaucome
DE60225845D1 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie

Legal Events

Date Code Title Description
8364 No opposition during term of opposition